- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017
Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board of Directors of a resolution changing the Company’s fiscal year-end from July 31 to December 31, today reported financial results for the transition period of August 1, 2017, through December 31, 2017, and provided a corporate update. …
Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board of Directors of a resolution changing the Company’s fiscal year-end from July 31 to December 31, today reported financial results for the transition period of August 1, 2017, through December 31, 2017, and provided a corporate update.
As quoted in the press release:
“After successfully paying back SWK its original investment in 2017, thereby reverting back to a right to receive 90% of royalty and milestone payments related to NARCAN® Nasal Spray and a robust clinical development pipeline advancing as planned, we entered 2018 in a much stronger operating position,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “NARCAN® continues to gain commercial traction, which resulted in Opiant recording a total of approximately $11.7 million in royalty and milestone revenue for the five-month period from August 1 through December 31, 2017. In addition, our promising pipeline was further strengthened following the recent positive data from our Phase I clinical study of OPNT003 (intranasal nalmefene) for the treatment of opioid overdose. Based on feedback from the U.S. Food and Drug Administration (FDA), we intend to pursue a 505(b)(2) development path for OPNT003, with the potential to submit a New Drug Application (NDA) for this product candidate in 2020.”
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2241.55 | -3.42 | |
Silver | 24.98 | -0.17 | |
Copper | 4.05 | +0.05 | |
Oil | 83.95 | +0.78 | |
Heating Oil | 2.64 | +0.01 | |
Natural Gas | 1.84 | +0.08 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.